HER2 positive breast cancer
Not recruitingStudy of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy
Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy
- Disease:HER2 positive breast cancer
- Substances:AnastrozoleExemestane+5
France- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Unicancer






